A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
暂无分享,去创建一个
A. Naranjo | J. Maris | W. London | Malcolm A. Smith | R. Seeger | M. Diccianni | A. Yu | K. Messer | B. Shulkin | M. Parisi | C. Reynolds | Julie R. Park | P. Sondel | A. Yu | M. Ozkaynak | A. Gilman | Sheena C. Tenney | L. Smith
[1] N. Hosten,et al. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO , 2017, mAbs.
[2] E. Socha,et al. Expression of IL-17A concentration and effector functions of peripheral blood neutrophils in food allergy hypersensitivity patients , 2016, International journal of immunopathology and pharmacology.
[3] K. Neville,et al. Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy , 2016, Cancer Chemotherapy and Pharmacology.
[4] W. Furman,et al. Comparison of pain outcomes between two anti‐GD2 antibodies in patients with neuroblastoma , 2015, Pediatric blood & cancer.
[5] J. Maris,et al. Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma , 2014, Cancer Chemotherapy and Pharmacology.
[6] KyungMann Kim,et al. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] B. Prakken,et al. Cytokine assays: an assessment of the preparation and treatment of blood and tissue samples. , 2013, Methods.
[8] Wentian Li,et al. Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. , 2011, Blood.
[9] Hao Liu,et al. An integrated proteomic approach to identifying circulating biomarkers in high‐risk neuroblastoma and their potential in relapse monitoring , 2011, Proteomics. Clinical applications.
[10] V. Pistoia,et al. Cytokines in neuroblastoma: from pathogenesis to treatment. , 2011, Immunotherapy.
[11] N. Cheung,et al. Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Maris,et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Helen X. Chen,et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.
[14] R. Khalil,et al. Inflammatory cytokines in vascular dysfunction and vascular disease. , 2009, Biochemical pharmacology.
[15] I. Tannock,et al. Cytokines and their relationship to the symptoms and outcome of cancer , 2008, Nature Reviews Cancer.
[16] D. Hougaard,et al. Effects of blood sample handling procedures on measurable inflammatory markers in plasma, serum and dried blood spot samples. , 2008, Journal of immunological methods.
[17] K. Takatsu,et al. IL-5 and eosinophilia. , 2008, Current opinion in immunology.
[18] O. Wagner,et al. Activation of endothelium by immunotherapy with interleukin‐2 in patients with malignant disorders , 1999, British journal of haematology.
[19] S. Larson,et al. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. , 1998, International journal of oncology.
[20] M. Uttenreuther-Fischer,et al. Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients , 1995, Cancer Immunology, Immunotherapy.
[21] H. Niitani,et al. [Phase II study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.
[22] T. Taguchi,et al. [Phase I study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.
[23] F. Berthold,et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.
[24] H. Langstein,et al. Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis. , 1991, The Journal of clinical investigation.
[25] S. Gillies,et al. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. , 1989, Journal of immunological methods.
[26] T. Kipps,et al. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. , 1989, Cancer research.
[27] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[28] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[29] A. Orucevic,et al. The role of active inducible nitric oxide synthase expression in the pathogenesis of capillary leak syndrome resulting from interleukin-2 therapy in mice. , 1997, Laboratory investigation; a journal of technical methods and pathology.